MM&M Awards finalists unveiled next week

Share this article:
The judges' scores are in for the MM&M Awards 2008 submissions and the shortlist of finalists in each category will be revealed simultaneously in the News Brief and at mmm-online.com next Tuesday, July 22.

Yesterday, more than 40 of the finest leaders and thinkers in healthcare marketing converged on a hotel in midtown New York to review and score a record-breaking 831 entries to the program.

The esteemed judging panel included Deborah Dunsire, president and CEO of Millennium Pharmaceuticals; Joe Shields, product director at Wyeth; Meryl Weinreb, director of patient programs, oncology, at AstraZeneca; Cynthia North, customer marketing director at Bayer HealthCare Pharmaceuticals; Ben Lei, group product manager at Genentech; Joan Mikardos, media director at Sanofi-Aventis; Jennifer Rinaldo, director of marketing at Forest Labs; Mike Pucci, VP, external advocacy at GlaxoSmithKline; Kevin Nalty, product director at Merck; and Stephen Calabrese, associate director of emarketing at Novartis Oncology.

Agency executives were also well-represented, including Doug Burcin, worldwide managing director at Euro RSCG Life Worldwide; Richard Nordstrom, CEO of McCann Healthcare Worldwide; and Sam Welch, CEO of Saatchi & Saatchi Healthcare Communications Group.

Experts from the media space included Jack Barrette, CEO of Wego Health; Marjorie Martin, SVP, general manager at Everyday Health; Bob Ziltz, publisher of Prevention magazine; and Keith Yokum, director of online advertising for the New England Journal of Medicine.

The 24 winners will once again be kept under wraps—even the judges won't know who they are—until the spectacular awards presentation evening at New York's Tavern on the Green on October 30, 2008. Tickets go on sale next week.
Share this article:
You must be a registered member of MMM to post a comment.

Email Newsletters

More in News

Five things for Pharma Marketers to know: Friday, August 29

Five things for Pharma Marketers to know: Friday, ...

Takeda closes out a good-news, bad-news kind of week, AstraZeneca adds a new clinical trial for its experimental PD-1, and researchers link a funeral to the Ebola outbreak.

Amgen sends PCSK9 to FDA

Amgen sends PCSK9 to FDA

Evolocumab holds the FDA's first filed biologics license application for the class.

Consultants expect M&A tempo to continue

Consultants expect M&A tempo to continue

PwC anticipates that divestitures will fuel late-2014 deals, but notes that the noise around early deals and the financials don't fully match up.